Celldex Therapeutics share price today
(NASDAQ: CLDX)

Name: Celldex Therapeutics Share Price Today (NASDAQ: CLDX) - Celldex Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Celldex Therapeutics share price is $24.48 & ₹2,117.28 as on 24 Jan 2025, 2.30 'hrs' IST

$24.48

▲

0.24

(0.99%)

Market is closed - opens 8 PM, 24 Jan 2025

View live Celldex Therapeutics share price in Dollar and Rupees. Guide to invest in Celldex Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Celldex Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Celldex Therapeutics share price movements

Today's Low: $23.59
Today's High: $24.58
$24.48
3.64%
Downside
Day's Volatility :4.03%
Upside
0.41%
52 Weeks Low: $22.17
52 Weeks High: $53.18
$24.48
9.46%
Downside
52 Weeks Volatility :58.32%
Upside
53.97%

Celldex Therapeutics Returns

Period	Celldex Therapeutics, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-10.06%	-5.5%	0.0%
6 Months	-45.6%	-4.3%	0.0%
1 Year	-35.08%	1.6%	0.0%
3 Years	-17.55%	9.8%	-11.0%

Celldex Therapeutics Key Statistics

in dollars & INR

Previous Close	$24.24
Open	$23.93
Today's High	$24.58
Today's Low	$23.59
Market Capitalization	$1.6B
Today's Volume	$511.1K
52 Week High	$53.18
52 Week Low	$22.165
Revenue TTM	$10.0M
EBITDA	$-171.1M
Earnings Per Share (EPS)	$-2.58
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-29.84%

How to invest in Celldex Therapeutics Stock (CLDX) from India?

It is very easy for Indian residents to invest directly in Celldex Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Celldex Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Celldex Therapeutics or CLDX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Celldex Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Celldex Therapeutics shares which would translate to 0.035 fractional shares of Celldex Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Celldex Therapeutics, in just a few clicks!

Returns in Celldex Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

Celldex Therapeutics investment value today

Current value as on today

₹69,614

Returns

₹30,386

(-30.39%)

Returns from Celldex Therapeutics Stock

₹34,440 (-34.44%)

Dollar Returns

₹4,054 (+4.05%)

Indian investors sentiment towards Celldex Therapeutics

-47%

Period: Oct 25, 2024 to Jan 23, 2025. Change in 30 Days versus previous period

Search volume for Celldex Therapeutics on INDmoney from India has reduced in the last 30 days as on Jan 24, 2025. -47% less investors are searching Celldex Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Celldex Therapeutics

Wellington Management Company LLP
13.93%
FMR Inc
9.08%
BlackRock Inc
7.36%
Vanguard Group Inc
5.83%
Kynam Capital Management, LP
5.21%
Eventide Asset Management, LLC
5.02%

Analyst Recommendation on Celldex Therapeutics

Buy

85%Buy

14%Hold

0%Sell

Based on 14 Wall street analysts offering stock ratings for Celldex Therapeutics(by analysts ranked 0 to 5 stars)

Based on 14 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Celldex Therapeutics

What analysts predicted

Upside of 174.1%

Target:

$67.10

Current:

$24.48

Insights on Celldex Therapeutics

Price Movement
In the last 7 days, CLDX stock has moved up by 6.5%
Increasing Revenue
Revenue is up for the last 3 quarters, 156.0K → 3.19M (in $), with an average increase of 57.7% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -32.80M → -42.12M (in $), with an average decrease of 13.4% per quarter
CLDX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 40.5% return, outperforming this stock by 77.7%
CLDX vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 95.4% return, outperforming this stock by 108.4%
Price to Sales
ForCLDX every $1 of sales, investors are willing to pay $147.8, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.1 for every $1 of sales.

Celldex Therapeutics Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$9.5M	↓ 25.15%
Net Income	$-151.2M	↑ 62.51%
Net Profit Margin	-1.6K%	↓ 855.01%

	FY19	Y/Y Change
Revenue	$3.6M	↓ 62.54%
Net Income	$-50.4M	↓ 66.68%
Net Profit Margin	-1.4K%	↑ 175.27%

	FY20	Y/Y Change
Revenue	$7.4M	↑ 107.61%
Net Income	$-59.8M	↑ 18.68%
Net Profit Margin	-805.88%	↑ 603.92%

	FY21	Y/Y Change
Revenue	$4.7M	↓ 37.3%
Net Income	$-70.5M	↑ 17.95%
Net Profit Margin	-1.5K%	↓ 710.16%

	FY22	Y/Y Change
Revenue	$2.4M	↓ 49.32%
Net Income	$-122.8M	↑ 74.13%
Net Profit Margin	-5.2K%	↓ 3693.25%

	FY23	Y/Y Change
Revenue	$6.9M	↑ 192.02%
Net Income	$-141.4M	↑ 15.19%
Net Profit Margin	-2.1K%	↑ 3154.53%

	Q2 FY23	Q/Q Change
Revenue	$268.0K	↓ 72.29%
Net Income	$-30.5M	↑ 36.08%
Net Profit Margin	-11.4K%	↓ 9063.35%

	Q3 FY23	Q/Q Change
Revenue	$1.5M	↑ 466.04%
Net Income	$-38.3M	↑ 25.43%
Net Profit Margin	-2.5K%	↑ 8859.26%

	Q4 FY23	Q/Q Change
Revenue	$4.1M	↑ 172.31%
Net Income	$-43.3M	↑ 13.19%
Net Profit Margin	-1.0K%	↑ 1473.76%

	Q1 FY24	Q/Q Change
Revenue	$156.0K	↓ 96.22%
Net Income	$-32.8M	↓ 24.24%
Net Profit Margin	-21.0K%	↓ 19982.45%

	Q2 FY24	Q/Q Change
Revenue	$2.5M	↑ 1501.28%
Net Income	$-35.8M	↑ 9.25%
Net Profit Margin	-1.4K%	↑ 19595.94%

	Q3 FY24	Q/Q Change
Revenue	$3.2M	↑ 27.74%
Net Income	$-42.1M	↑ 17.52%
Net Profit Margin	-1.3K%	↑ 114.84%

	FY18	Y/Y Change
Profit	$9.5M	↓ 25.15%

	FY19	Y/Y Change
Profit	$-39.1M	↓ 509.93%

	FY20	Y/Y Change
Profit	$-35.1M	↓ 10.19%

	FY21	Y/Y Change
Profit	$1.6M	↓ 104.51%

	FY22	Y/Y Change
Profit	$957.0K	↓ 39.55%

	FY23	Y/Y Change
Profit	$3.9M	↑ 304.91%

	Q2 FY23	Q/Q Change
Profit	$-488.0K	↓ 302.49%

	Q3 FY23	Q/Q Change
Profit	$750.0K	↓ 253.69%

	Q4 FY23	Q/Q Change
Profit	$3.4M	↑ 349.6%

	Q1 FY24	Q/Q Change
Profit	$-619.0K	↓ 118.36%

	Q2 FY24	Q/Q Change
Profit	$1.7M	↓ 374.8%

	Q3 FY24	Q/Q Change
Profit	$3.2M	↑ 87.6%

	FY18	Y/Y Change
Operating Cash Flow	$-75.2M	↓ 24.71%
Investing Cash Flow	$29.8M	↓ 35.84%
Financing Cash Flow	$29.4M	↓ 42.6%

	FY19	Y/Y Change
Operating Cash Flow	$-46.4M	↓ 38.31%
Investing Cash Flow	$17.1M	↓ 42.72%
Financing Cash Flow	$16.3M	↓ 44.78%

	FY20	Y/Y Change
Operating Cash Flow	$-40.4M	↓ 12.95%
Investing Cash Flow	$-98.2M	↓ 675.05%
Financing Cash Flow	$171.2M	↑ 953.24%

	FY21	Y/Y Change
Operating Cash Flow	$-60.9M	↑ 50.75%
Investing Cash Flow	$-216.2M	↑ 120.08%
Financing Cash Flow	$272.4M	↑ 59.07%

	FY22	Y/Y Change
Operating Cash Flow	$-103.7M	↑ 70.31%
Investing Cash Flow	$89.9M	↓ 141.61%
Financing Cash Flow	$4.1M	↓ 98.5%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-27.2M	↓ 4.81%
Investing Cash Flow	$1.2M	↓ 97.79%
Financing Cash Flow	$133.0K	↓ 80.84%

Celldex Therapeutics Technicals Summary

Sell

Neutral

Buy

Celldex Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Celldex Therapeutics Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Celldex Therapeutics, Inc.	-3.54%	-45.6%	-35.08%	-17.55%	977.33%
Biontech Se	0.91%	34.01%	18.85%	-26.4%	246.9%
Regeneron Pharmaceuticals, Inc.	-4.82%	-36.95%	-28.33%	12.74%	100.35%
Vertex Pharmaceuticals Incorporated	4.86%	-13.58%	-0.46%	88.45%	88.24%
Alnylam Pharmaceuticals, Inc.	9.57%	13.5%	44.91%	103.56%	127.75%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Celldex Therapeutics, Inc.	NA	NA	0.0	-2.4	-0.3	-0.2	NA	11.85
Biontech Se	160.8	NA	0.04	-3.33	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	17.02	17.02	1.05	44.99	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.1	0.48	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Celldex Therapeutics, Inc.	Buy	$1.6B	977.33%	NA	0.0%
Biontech Se	Buy	$28.1B	246.9%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$75.6B	100.35%	17.02	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$110.2B	88.24%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$34.2B	127.75%	NA	-15.86%

Celldex Therapeutics Dividend announcements

Celldex Therapeutics Earnings
Celldex Therapeutics’s price-to-earnings ratio stands at None
Read More

About Celldex Therapeutics

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Organization	Celldex Therapeutics
Employees	160
CEO	Mr. Anthony S. Marucci M.B.A.
Industry	Health Technology

Management People of Celldex Therapeutics

Name	Title
Mr. Anthony S. Marucci M.B.A.	Founder, President, CEO & Director
Dr. Tibor Keler Ph.D.	Founder, Chief Scientific Officer & Executive VP
Mr. Sam Martin CPA	Senior VP, CFO, Secretary & Treasurer
Dr. Margo Heath-Chiozzi M.D.	Senior Vice President of Regulatory Affairs
Dr. Diane C. Young M.D.	Senior VP & Chief Medical Officer
Prof. Joseph P. Schlessinger Ph.D.	Co-Founder & Member of Scientific Advisory Board
Ms. Sarah Cavanaugh	Senior Vice President of Corporate Affairs & Administration
Mr. Freddy A. Jimenez Esq.	Senior VP & General Counsel
Dr. Ronald A. Pepin	Chief Business Officer & Senior VP
Ms. Elizabeth Crowley	Chief Product Development Officer & Senior VP

Important FAQs about investing in Celldex Therapeutics (CLDX) from India :

What is Celldex Therapeutics share price today?

Celldex Therapeutics share price today stands at $24.48, Open: $23.93 ; Previous Close: $24.24 ; High: $24.58 ; Low: $23.59 ; 52 Week High: $53.18 ; 52 Week Low: $22.17. The stock opens at $23.93, after a previous close of $24.24. The stock reached a daily high of $24.58 and a low of $23.59, with a 52-week high of $53.18 and a 52-week low of $22.17.

Can Indians buy Celldex Therapeutics shares?

Yes, Indians can invest in the Celldex Therapeutics (CLDX) from India.

With INDmoney, you can buy Celldex Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Celldex Therapeutics at zero transaction cost.

How can I buy Celldex Therapeutics shares from India?

It is very easy to buy Celldex Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Celldex Therapeutics be purchased?

Yes, you can buy fractional shares of Celldex Therapeutics with INDmoney app.

What are the documents required to start investing in Celldex Therapeutics stocks?

To start investing in Celldex Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.